Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 6051 - 6075 of 10204 in total

Diundecyl Phosphatidyl Choline

Experimental
Matched Iupac: … [(2R)-2,3-bis(dodecanoyloxy)propoxy][2-(trimethylazaniumyl)ethoxy]phosphinic acid …

Di-Stearoyl-3-Sn-Phosphatidylcholine

Experimental
Matched Name: … Di-Stearoyl-3-Sn-Phosphatidylcholine …
Matched Iupac: … [(2R)-2,3-bis(octadecanoyloxy)propoxy][2-(trimethylazaniumyl)ethoxy]phosphinic acid …

7-(1-ETHYL-PROPYL)-7H-PYRROLO-[3,2-F]QUINAZOLINE-1,3-DIAMINE

Experimental
Matched Iupac: … 7-(pentan-3-yl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine …

4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol

Experimental
Matched Name: … 4-[(6-phenyl[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]phenol …
Matched Iupac: … 4-({6-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl}methyl)phenol …

Peptide YY (3-36)

Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.
Investigational
Matched Synonyms: … PYY 3-36 ... PYY(3-36) ... Pyy (3-36) peptide …
Matched Name: … Peptide YY (3-36) …
Matched Description: … Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity …

6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE

Experimental

Ralimetinib

Ralimetinib has been used in trials studying the treatment of Postmenopausal, Advanced Cancer, Adult Glioblastoma, Fallopian Tube Cancer, and Metastatic Breast Cancer, among others.
Investigational
Matched Iupac: … 5-[2-tert-butyl-5-(4-fluorophenyl)-1H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin- ... 2-amine …

(1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL]ETHYL]-1-NAPHTHALENOL

Experimental
Matched Name: … (1S,7S,8S,8AR)-1,2,3,7,8,8A-HEXAHYDRO-7-METHYL-8-[2-[(2R,4R)-TETRAHYDRO-4-HY DROXY-6-OXO-2H-PYRAN-2-YL …
Matched Iupac: … -2-one ... (4R,6S)-6-{2-[(1S,2S,8S,8aR)-8-hydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]ethyl}-4-hydroxyoxan …

Oxypurinol

Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.
Investigational

VLTS-589

VLTS-589 consists of plasmid encoding the angiomatrix protein Del-1 in conjunction with poloxamer 188 for the treatment of peripheral vascular disease.
Investigational

NP-50301

NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational

SNX-5422

SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
Matched Iupac: … (1r,4r)-4-({2-carbamoyl-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl] ... phenyl}amino)cyclohexyl 2-aminoacetate …
Matched Categories: … Heterocyclic Compounds, 2-Ring …

KRN-5500

KRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic Solid Tumors).
Investigational
Matched Iupac: … 3-yl]carbamoyl}methyl)tetradeca-2,4-dienamide ... (2E,4E)-N-({[(2R,3R,4R,5R,6S)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxy-6-[(9H-purin-6-yl)amino]oxan- …
Matched Categories: … Heterocyclic Compounds, 2-Ring …

V590

The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578]. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose . Other features of...
Investigational

AZD-5069

Investigational
Matched Iupac: … N-(2-{[(2,3-difluorophenyl)methyl]sulfanyl}-6-{[(2R,3S)-3,4-dihydroxybutan-2-yl]oxy}pyrimidin-4-yl)azetidine …

TERT-572

Investigational

KITE-585

KITE-585 is an autologous, fully-human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy. It is being investigated in the treatment of multiple myeloma.
Investigational

ABBV-514

ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.
Investigational

DPI59

Experimental

AZD-5672

Azd5672 has been used in trials studying the basic science and treatment of Pharmacokinetics, Renal Impairment, and Rheumatoid Arthritis.
Investigational
Matched Iupac: … N-{1-[(3R)-3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl]piperidin-4-yl}-N-ethyl-2-(4-methanesulfonylphenyl …

AZD-5423

AZD5423 has been used in trials studying the basic science and treatment of Asthma, Bioavailability and AUC, and Chronic Obstructive Pulmonary Disease (COPD).
Investigational
Matched Iupac: … 2,2,2-trifluoro-N-[(1R,2S)-1-{[1-(4-fluorophenyl)-1H-indazol-5-yl]oxy}-1-(3-methoxyphenyl)propan-2-yl …
Matched Categories: … Heterocyclic Compounds, 2-Ring …

AZD-5991

AZD-5991 is under investigation in clinical trial NCT03218683 (Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.).
Investigational

NDI-5001

Investigational

MOD-5014

MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational

BHV-5000

BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is lanicemine.
Investigational
Displaying drugs 6051 - 6075 of 10204 in total